Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) has reported second-quarter 2026 net product revenue of approximately $13.5 million, a significant increase from $2 million in the same period last year. The growth was primarily driven by approximately $11 million in net sales of TONMYA, the company’s recently approved treatment for fibromyalgia. During the quarter, TONMYA recorded 12,592 total prescriptions, a 100% sequential increase. New patient prescriptions rose 36%, while refills surged 207%, indicating strong adoption and patient adherence.
TONMYA’s market access has expanded substantially, with coverage now representing approximately 136 million lives across commercial, managed Medicare, and Medicaid channels. This coverage is expected to grow to approximately 145 million lives when a managed Medicare agreement takes effect on January 1, 2027. This broad coverage is crucial for patient access and commercial success.
In addition to the commercial performance, Tonix continues to advance its clinical pipeline. The company has enrolled the first patient in the potentially pivotal Phase 2 HORIZON study evaluating TNX-102 SL for major depressive disorder. Furthermore, Tonix is preparing to begin an adaptive Phase 2 field study of TNX-4800 for Lyme disease prevention in the first quarter of 2027, pending final FDA review and agreement on the protocol. These developments underscore Tonix’s commitment to addressing high unmet medical needs in central nervous system (CNS) and immunology.
The company ended the quarter with approximately $176.2 million in cash and cash equivalents. Management stated that these resources, along with third-quarter equity proceeds to date, are expected to fund planned operations and capital expenditures into early second-quarter 2027. This financial runway provides stability as the company continues to commercialize TONMYA and advance its pipeline.
Tonix Pharmaceuticals is a fully integrated, commercial-stage biotechnology company focused on CNS and immunology treatments. TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg) is the first new treatment for fibromyalgia in more than 15 years, representing a significant advancement for patients. The company’s CNS commercial infrastructure also supports its acute migraine products, Zembrace SymTouch and Tosymra. Tonix is exploring TONMYA’s potential in other indications, including major depressive disorder and acute stress disorder, through Phase 2 clinical trials.
Beyond TONMYA, Tonix’s CNS portfolio includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. The company is also advancing immunology programs, including TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. These programs highlight the company’s broad research and development efforts.
The strong quarterly results and pipeline progress position Tonix for potential growth in the coming years. The expansion of TONMYA’s coverage and prescription trends are positive indicators for the company’s commercial trajectory. As the company continues to execute on its strategic priorities, investors and industry observers will be watching for further updates on clinical trials and market adoption.
For more information, visit the company’s newsroom at https://nnw.fm/TNXP.
